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Abstract
Background: Platelet-rich plasma (PRP) has been used to support tendon regeneration mainly in sports medicine.
PRP is a concentrate of platelet-rich plasma proteins derived from whole blood by centrifugation to remove
erythrocytes and leukocytes. PRP has high amounts of platelets which may promote healing tendons affected by
degenerative conditions. These platelets contain growth factors and are known to facilitate the regeneration of
injured tendon structures. Total hip arthroplasty (THA) through the Hardinge approach may leave the patient with
impaired gait and poor regeneration of the gluteus medius tendon if the tendon is not reattached properly after
closure of the surgical wound.
Methods: The study will be a multicenter, double-blinded and randomized study enrolling 90 patients based on
power calculations. The efficacy of perioperative PRP treatment will be assessed by subjective and objective outcome
variables. The participants will be randomized (sealed envelope) into either a placebo (saline) or a PRP group (1:1). For
subjective outcomes, the Oxford Hip Score (OHS) will be collected before surgery and 3 and 12 months after surgery.
The objective measures are findings at magnetic resonance imaging and plain radiographs and recorded values of
measured strength.
Discussion: We present the perioperative use and the ways to measure the clinical efficacy of PRP. As PRP may have
benefits regarding degenerative tendon regeneration, studies on the use of PRP in hip arthroplasty are warranted to
facilitate postoperative recovery.
Trial registration: This study has been approved by the ethics committee of the Hospital District of Southwest Finland
and approved by the local institutional research board. The study has been registered in ClinicalTrials.gov
(NCT02607462).
Background
Total hip arthroplasty (THA) is a common orthopedic
procedure (Kurtz et al. 2007). In Finland, over 8000 hip
arthroplasty procedures have been made annually since
2012 due to osteoarthritis (OA) (Finnish Arthroplasty
Register 2015). Recently, an American arthroplasty regis-
ter study found that the total distribution of arthroplasty
procedures in the United States was 860,080 of which
32,2% (277,200) were total hip arthroplasties (AJJR an-
nual Report 2017). Kurz et al. estimated that by 2030,
the demand for primary THA in the US will grow by
174% to 572,000 (Kurtz et al. 2007) and this increasing
trend seems to be a worldwide phenomenon (Kurtz et
al. 2010).
Two commonly used approaches in THA are the
Moore approach (posterior approach) and the modified
Hardinge approach (direct lateral approach) (Pellicci et
al. 1998; Hardinge 1982; Finnish Arthroplasty society
2015; Madsen et al. 2004). Other possible approaches
are the Smith-Petersen direct anterior approach and the
Watson-Jones anterolateral approach (Smith-Petersen
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1949; Watson-Jones 1934). Chechik et al. surveyed 292
orthopedic surgeons from 57 countries and found that
the posterior approach was used by 45% and the direct
lateral approach by 42%. The anterior approach was
used by 10% of the surgeons and other approaches by
3% (Chechik et al. 2013).
Six months after THA up to 85% and 2 years after THA
up to 10% of patients may experience abduction weakness
of the hip muscles (Madsen et al. 2004; Mulliken et al.
1998). This complication seems to be associated with the
surgical approach used. When the Hardinge approach is
used, the gluteus medius and minimus muscles are split to
allow anterior dislocation of the hip; at the end of the
operation, these muscles are attached to their insertion
(Mulliken et al. 1998). Residual abductor and limb weak-
ness may result from avulsion of the repair of the anterior
portion of the abductors or from direct injury to the
superior gluteal nerve. The occurrence of these complica-
tions (positive Trendelenburg sign and abnormal gait) is
reportedly no less than 11% (Havelin et al. 2016; Ramesh
et al. 1996). When the posterior approach is used and the
gluteus medius remains intact, these complications can be
avoided (Petis et al. 2015). Different approaches lead to
different complications (Petis S et al. 2015). A well-known
risk of the posterior approach is femoral dislocation, the
rate of which is 1–5% (Petis et al. 2015; Jolles et al. 2006).
Careful reconstruction of the joint capsule and short
external rotators may decrease the risk of postoperative
dislocation (Kwon et al. 2006).
Platelet rich plasma (PRP) is used in various areas of
surgery to enhance bone and soft-tissue repair by close
proximity of supraphysiological concentrations of
autologous platelets at the site of tissue damage. The α
granules of platelets are rich in growth factors that are
essential for tissue repair: transforming growth factor-β,
vascular endothelial growth factor and platelet-derived
growth factor (Alsousou et al. 2009). The interaction be-
tween these growth factors and surface receptors on the
target cells activates intracellular signaling pathways that
induce the production of proteins needed for the regen-
erative processes, such as cellular proliferation, matrix
formation, osteoid production and collagen synthesis
(Schliephake 2002).
PRP can be prepared in a laboratory, the operating
room or clinic room immediately before surgery. There
are three methods for preparation: gravitational platelet
sequestration (GPS), standard cell separation and autolo-
gous selective filtration (thrombapheresis) (Alsousou et
al. 2009). Because PRP is prepared from autologous
blood it is inherently safe. Any concerns associated with
allografts or xenografts regarding transmission of
diseases, such as HIV, hepatitis or Creutzfeld-Jakob
disease, or of immunogenic reactions are eliminated
(Man et al. 2001).
The increased awareness of the effectiveness of PRP in
musculoskeletal healing has expanded its indications in
orthopedic and sports medicine (Fitzpatrick et al. 2017).
A randomized controlled study reported that intra-
articular PRP injections offer significant clinical im-
provement for patients with hip osteoarthritis but is void
of substantial side effects (Man et al. 2001). Topical PRP
in total knee arthroplasty (TKA) reduces postoperative
blood loss (Mochizuki et al. 2016; Aggarwal et al. 2014).
PRP reduces pain after TKA (Aggarwal et al. 2014). On
the other hand, a recent systematic review stated that
the number of high quality RCT’s investigating the use
of PRP in knee osteoarthritis is limited (Muchedzi et al.
2017). In a retrospective analysis there was no clinical
benefit from the use of PRP in THA (Safdar et al. 2015).
To our knowledge, no randomized controlled trials
(RCT) have published on the effectiveness of PRP in
musculoskeletal tissue healing at THA procedure.
In this paper, we describe the protocol of our ongoing
randomized controlled trial assessing the effects of PRP
in minimizing postoperative problems for patients who
have undergone THA with the Hardinge approach.
Methods and analysis
Objectives and study hypothesis
The objective of this trial is to compare the healing of the
gluteus medius insertion among patients who have under-
gone THA. We will operate patients through the Hardinge
approach and inject PRP or placebo in the region of the
gluteus medius tendon insertion. The primary objective is
to investigate the healing of the gluteus medius insertion
objectively with MRI (anatomy) and hip strength mea-
surements (dynamometer). The secondary objective is to
record and analyze the changes in the Oxford Hip Score
(OHS) by comparing the OHS before and after surgery
and to record and analyze clinical signs, especially lim-
ping, pain and movement restrictions. The tertiary objec-
tive is to analyze safety and the cost-effectiveness of PRP
in THA. The hypothesis is that PRP facilitates postopera-
tive healing of the gluteus medius among elderly patients
after THA and that the healing can be verified objectively
seen by MRI and dynamometry.
Study design
The study is a multicenter RCT with parallel study
groups (1:1). The study design is double blinded where
neither the orthopedic surgeon nor the patient know
whether the patient receives PRP treatment or placebo.
The flowchart of the study cohort is shown in Fig. 1 in-
cluding enrollment, allocation, follow-up and analysis.
After having provided written informed consent the
patients are enrolled. They participate voluntary in the
study, they may withdraw from the trial at any time and
are not compelled to explain the reason for withdrawal.
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Enrollment began with a pilot phase conducted in a
secondary hospital in Finland, where the study protocol
was followed. A total of 18 patients were recruited. The
THA procedures was done by four orthopedic surgeons
experienced in the Hardinge approach and in injecting
PRP during closure. Postoperative open care visits to the
same orthopedic surgeons who performed the THA
were carried out and hip strength assessments were
done by a trained physiotherapist.
Patients
The patients will be recruited to the study from the
THA surgery queue. Patients who have been referred in
writing to the hospital (Päijät-Hämeen keskussairaala,
Lahti, Finland) for THA will receive a written invitation
to participate in the study. This invitation will be sent to
the patient together with the invitation to attend for an
open care visit at the hospital for preoperative assess-
ment for the THA. During the this interview the patient
discusses the treatment plan with the operating
orthopedic surgeon, after which one of the study physi-
cians (AA or JK) will provide detailed information about
the study. Then a from for providing written informed
consent is handed to the patient. After the interview pa-
tient will have 2 weeks time to get familiar with the
study and consider participation in the study. After this,
the patient will have the option to sign and submit the
consent form or to decline to do so when arriving to the
hospital for the THA.
The inclusion and exclusion criteria are shown in
Table 1. Patinets aged 60–75 years are eligible. This age
span has been decided upon based on the profile of the
patients undergoing THA in Finland and who are
eligible for cementless THA (Mäkelä et al. 2008). The
other inclusion criteria (degree of osteoarthritis and clin-
ical symptoms) will be determined by the orthopedic
surgeon who decides if the THA procedure is to the
probable benefit of the patient (Table 1). The exclusion
criteria are based on the conceivable complications
related to PRP or rehabilitation.
Fig. 1 Flowchart of the trial: enrollment, treatment allocation and follow-up scheme
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Preparation of PRP, placebo
For the preparation of PRP, 50 ml of fresh venous
blood with 5 ml sodium citrate (anticoagulant) will be
collected into a single syringe from an antebrachial
vein. The collected venous blood will be separated
into 4 × 10 ml PRP-syringes (GLO PRP kit™, Glotech
Co, Korea) for centrifugation. The PRP will be done
according the manufacturer’s instructions with 2
separate centrifugations: the first centrifugation will
be for 5 min at 1200 rpm and the second for 2 min
and 1200 rpm. After the first centrifugation, red
blood cells will be collected and discarded. The
second centrifugation will be used to concentrate the
platelets and separate the buffy-coat from the PRP.
From each PRP-syringe, 2.5 ml of concentrated PRP
will be collected from the bottom of the syringe and
10 ml of PRP ready for injection will be produced. Of
the 10 ml, a 1 ml sample will be taken for laboratory
analysis. The placebo consists of saline, and has been
found to be appropriate (Schöffl et al. 2017).
Baseline
The primary OA diagnosis will be made by the ortho-
pedic surgeon who assesses whether the patient benefits
from THA. In support of this decision, the surgeon will
have access to plain radiographs of the affected hip joint
and information on the range of movements of the hip
joint. Inclusion mandates that the patient has OA
Kellgren-Lawrence grade 3–4. The strength of both hips
at baseline will be assessed by a physiotherapist on the
day of surgery and the baseline OHS will be calculated
and recorded.
Interventions
The THA procedure will be done per routine so that the
gluteus medius muscle is partly stripped from its tro-
chanteric insertion during the approach to the hip joint.
This stripped part of the gluteus medius muscle will be
sutured back to the insertion site with non-absorbable
sutures via bone tunnels at the closure phase of the pro-
cedure. The blinded placebo or PRP will be injected into
the tendon incision line of the gluteus medius (Fig. 2)
and targeted into the bone tendon interval. No leakage
of PRP is expected after injection, since PRP will be
injected at multiple sites after closure with bone tunnels
and non-absorpable sutures (Ethibond nro. 1, Ethicon/
Johnson-Johnson).
The postoperative rehabilitation will follow national
guidelines: the patient is mobilized with full weight bearing
and free range of movements. The rehabilitation protocol is
of beneficit to the patient (Tsukagoshi et al. 2014;
Andersson et al. 2001). Cruches will be used primary for
safe mobilization and a physiotherapist will give detailed in-
structions for postoperative rehabilitation to each patient.
Randomisation and concealment
The final decision of inclusion or exclusion of the
patient into the trial will be done during the THA
procedure where the surgeon will evaluate the condition
of the gluteus medius. If the gluteus medius seems
abnormal (i.e., torn or atrophied), the patient will be
withdrawn from the study. If gluteus medius is intact,
the surgeon will notify the staff nurse who will open a
sealed envelope. The sealed envelopes will be kept in a
secure and agreed location known only to the trial physi-
cians and nurses; the surgeon will not know which
group the participant is included. If the patient is allo-
cated to receive placebo, 50 ml of blood will be drawn
but the blood will not be prepared for PRP. The venous
sample will be taken and PRP prepared by a study
Table 1 Inclusion and exclusion criteria
Inclusion criteria (all of the following):
1. Age 60–75 years
2. Plain x-rays showing osteoarthritis (Kellgren and Lawrence
gradus 3–4) which correlates with clinical symptoms
3. Clinically symptomatic osteoarthritis requiring treatment with
total hip arthroplasty
Exclusion criteria (any one of the following):
1. Previous surgery of the affected joint
2. Post-traumatic arthritis
3. Rheumatoid arthritis and other autoimmune illnesses
4. Malignancy
5. Patients on oral glucocorticosteroids
6. Insulin-dependent diabetes
7. Smoking
8. Alcohol or drug abuse
9. Mental instability
Fig. 2 Injection site for PRP or placebo (marked with *). Black lines
indicate the suturation via bone tunnels
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physician (AA or JK) who will not participate the THA
surgery. Instead, after about 30 min the surgeon will be
given a blinded (taped) 10 ml syringe with saline by the
instrument nurse.
If the patient is randomized to receive PRP, 50 ml of
blood is drawn, as for the placebo procedure. This blood
will be prepared in an operation room behind the sur-
geons back. Then the surgeon will be given a blinded
(taped) 10 ml syringe with PRP.
Outcome measures
To measure objectively the healing of the gluteus medius
and to check the positions of the components of the
joint prosthesis, MRI and plain radiographs will be taken
3 and 12 months postoperatively. At the same control
visits, a trained physiotherapist will measure the hip
strengths and the OHS will be recorded. Clinical exami-
nations will be conducted (movements of both hip
joints, wound healing) and any limping or a positive
Trendelenburg sign will be recorded.
Oxford hip score
Patients will fill OHS forms preoperatively and postope-
ratively at 3 and 12 months after surgery.
Magnetic resonance imaging - MRI
MRI sequences will be used according to the MARS
protocol (Pfirrmann et al. 2005), where T1 sequences
will be used to identify gluteus medius pathology, and
coronal and sagittal images are taken. The imaging time
per sequence is about 3–6 min and the entire MRI study
will take approximately 30 min in total.
Clinical examination – gait and Trendelenburg test
The Trendelenburg test and the hip lag sign will be ex-
amined 3 and 12 months after the THA by the surgeon.
The hip lag sign is tested by putting the patient or his
side with the operated hip upwards and by asking the
patient to abduct the examined extremity. This testing
position mimics the validated hip strength
measurements used in the present study protocol and is
shown below.
Hip strength measurements
To test the reattachment and function of the detached
gluteus medius required by the Hardinge approach, hip
abduction strength will be measured with a dyna-
mometer. The abduction forces of both lower extre-
mities will be tested with the patient lying supine and on
his side (Fig. 3).
Reoperations, loss to follow-up and missing data
All reoperations, loss to follow-up and missing data will
be recorded. Patients who experience perioperative or
postoperative complications related to healing of the
gluteus medius (i.e., trochanteric fracture or infection)
will be censored from the final analysis. In order to
minimize loss to follow-up and missing data, the dates
for the postoperative visists will be set and given in writ-
ing to the patients already at the ward; this includes the
visit for strength assessment and clinical examinations.
MRI and radiography will be done during the same week
as the 3- and 12-month clinical control visits.
Data management and statistical analysis (sample size)
Due to multiple outcome settings, the OHS was used as
the primary outcome measure and power calculations
were carried out accordingly. Thus, a sample size of 40
patients per intervention group has been calculated as
being sufficient when a 5 point mean difference (SD
7.8 point) is used to identify a significant difference
at a significance level of 0.05 and 80% power (two-
sample t-test).
Ethics
The etics committee of the Hospital District of Southwest
Finland approved the study (ETMK 77/2015, 21.3.2017).
Fig. 3 Dynamometric hip strength measurement (Widler et al. 2009)
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Single versus multiple surgeons/centers
Although single-center studies in RCTs has been met
with criticism (Moseley et al. 2002), one of the main
purposes of the pilot study protocol was to generate a
logistically feasible setting which could be easily
transferred to any other primary, secondary or tertiary
hospital in Finland. As we want to know only the healing
of the gluteus medius, objective methods of follow-up
(MRI and strength assessment) will be used.
Pilot study results
Our pilot study results have been presented pre-
viously at the German Congress of Orthopaedics and
Traumatology 2017 (DKOU 2017) (Puhakka et al.
2017). A total of 12 patients participated in the pilot
study in the Satakunta Central Hospital, Finland. The
OHS of these patients increased in 3 months by 23.5
points in the PRP group compared to an increase of
20.2 points in the group who got placebo. The PRP
group had a higher average increase in the maximum
strength abduction compared to those who got pla-
cebo (39.1 vs. 6.2%). These preliminary results were
in line with the power analysis, where significant dif-
ferences (p < 0.05) are expected with 40 patients per
study groups. The basic charasteristics of the pilot
study group are given in Table 2.
Discussion
The present study protocol uses has several point-of-
care methods in an attempt to reveal if a single peri-
operative PRP injection into the reinsertion site of the
gluteus medius during THA benefits the patient. Firstly,
we will analyze MR images to examine the anatomy and
healing of the reattached gluteus medius. MRI is of high
clinical value in symptomatic THA patients who have a
compromised gluteus medius muscle (Pfirrmann et al.
2005). MRI can also reveal significant abductor atrophy
after THA (Engelken et al. 2014; Roth et al. 2014).
Secondly, OHS data will be collected for a detailed un-
derstanding of the overall patient outcome after THA.
Previously OHS has been compared to various hip
scores and it has been validated as a registry tool
(Nilsdotter et al. 2001). It has been shown that a change
in the total score of 4.85 is clinically meaningful (Beard
et al. 2015). Thirdly, clinical examination with special
attention to any gait abnormalities will be included.
Historically, the Trendelenburg sign has been used to
diagnose gluteus medius injuries, but the reliability of
this sign has been questioned (Youdas et al. 2010). Poor
abduction strength seems to be associated with abnor-
mal gait (limping). During gait, abduction of the lower
extremity is produced by the gluteus medius muscle
(Anderson et al. 2003). Kaltenborn et al. have created a
clinical sign – the hip lag sign – which correlates with
the degree of gluteus medius impairment in MRI
(Kaltenborn et al. 2014). The reported specificity and
sensitivity of the hip lag sign is excellent, 96.5% and 89.
7%, respectively. In the present study the hip lag test will
be carried out augmented by dynamometric measure-
ments to assess the strength of the hip postoperatively.
This method has been validated for hip abduction power
measurements (Widler et al. 2009).
The need for THA will increase massively in the future
and research to identify more rapid and cost-effective
postoperative rehabilitation is needed. The present study
plan describes a RCT aimed at determining if PRP benefits
a given subgroup of THA patients.
Limitations
The main limitation of the study will be the use on non-
standardized PRP preparations. The amount of platelets
in a batch of PRP cannot be determined during the pro-
cedure and controlling the concentration of platelets
and leukocytes in a given batch of PRP is difficult
(Shahid & Kundra, 2017). Indeed, there have been no
studies which have solved the issue of how to
homogenize fresh PRP. Because the quantity of leuko-
cytes and platelets seems to be highly relevant, we will
take a 1 ml control sample from the final injectable PRP
and analyze it in the hospital laboratory. The control
sample will be taken in an EDTA-containing test tube to
Table 2 Basic characteristics of pilot study groups
Characteristic PRP n = 6 Placebo n = 6
Age, mean (range) 66.5 (63–72) 70.3 (68–73)
Gender (M / F) 3 / 3 5 / 1
Height (cm) 175 (165–183) 170 (156–179)
Weight (kg) 81.4 (72–90) 78.0 (63–87)
BMI 26.4 (25.5–26.9) 27.1 (21.3–30.1)
Illnesses
Type 2 DM, oral medication 1 1
High blood pressure medication 3 –
Coronary artery disease – 1
Hypercholesterolemia – 1
Platelet-rich plasma characteristics
Number of cells per patient (×106, mean, 9 ml)
Red blood cells 0.11 –
Leukocytes 1.10 –
Platelets 60.0
Concentrations (× 109, mean) –
Red blood cells 0.12 –
Leukocytes 1.21 –
Platelets 66.7
Aavikko et al. Journal of Experimental Orthopaedics  (2018) 5:23 Page 6 of 8
prohibit coagulation and delivered to the laboratory
within 30 min after sampling.
The study design does not allow distinguishing be-
tween muscle weakness due to the THA and damage to
the superior gluteal nerve. Presistant symptoms and clin-
ical signs of a positive Trendelenburg test due to the
nerve injury is rare (Petis et al. 2015). To detect a posi-
tive Trendelenburg test reliably, we could have added
postoperative gait assessment to the protocol, but since
gait analysis is not routinely used in the clinic, we have
not included this in the study protocol. No previous
studies have used gait analysis usefully in settings similar
to this stuidy.
Conclusion
This paper summarizes how randomization will be carried
out and describes the follow-up of patients with respect to
postoperative healing of the gluteus medius muscle with
objective and subjective methods. This placebo-controlled
RCT is designed to answer the question of whether inter-
vention with perioperative PRP applied in the area of the
gluteus medius tendon insertion affects the outcome of
patients who have undergone THA via Hardinge
approach.
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